Liver disease and COVID-19: from Pathogenesis to Clinical Care.

Fiche publication

Date publication

décembre 2020

Journal

Hepatology (Baltimore, Md.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas

Tous les auteurs :
Saviano A, Wrensch F, Ghany MG, Baumert TF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33332624

Résumé

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that emerged in late 2019 is posing an unprecedented challenge to global health. COVID-19, the clinical disease caused by SARS-CoV-2 has a variable presentation ranging from asymptomatic infection to life-threatening acute respiratory distress syndrome and multi-organ failure. Liver involvement is common during COVID-19 and exhibits a spectrum of clinical manifestations from asymptomatic elevations of liver function tests to hepatic decompensation. The presence of abnormal liver tests has been associated with a more severe presentation of COVID-19 disease and overall mortality. Although SARS-CoV-2 RNA has been detected in the liver of COVID-19 patients, it remains unclear whether SARS-CoV-2 productively infects and replicates in liver cells and has a direct liver-pathogenic effect. The cause of liver injury in COVID-19 can be attributed to multiple factors including virus-induced systemic inflammation, hypoxia, hepatic congestion and drug induced liver disease. Among patients with cirrhosis, COVID-19 has been associated with hepatic decompensation and liver-related mortality. Additionally, COVID-19's impact on healthcare resources can adversely affect delivery of care and outcomes of patients with chronic liver disease. Understanding the underlying mechanisms of liver injury during COVID-19 will be important in the management of COVID-19 patients, especially those with advanced liver disease. This review summarizes our current knowledge of SARS-CoV-2 virus-host interactions in the liver as well the clinical impact of liver disease in COVID-19.